30 C
Vientiane
Saturday, June 7, 2025
spot_img
Home Blog Page 122

Yunji Selects WWC, P.C. as its Independent Registered Public Accounting Firm

HANGZHOU, China, May 22, 2025 /PRNewswire/ — Yunji Inc. (“Yunji” or the “Company”) (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that the Company’s board of directors and the audit committee of the board approved the dismissal of PricewaterhouseCoopers Zhong Tian LLP (“PwC”) as the Company’s independent registered public accounting firm, effective May 22, 2025, and the appointment of WWC, P.C. (“WWC”) as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025, effective May 22, 2025.

The reports of PwC on the Company’s consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 contained no adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles.  

During the fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through May 22, 2025, there have been (i) no disagreements (as defined in Item 16F(a)(1)(iv) of Form 20-F) between the Company and PwC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PwC, would have caused PwC to make reference thereto in their reports on the Company’s consolidated financial statements for such years, and (ii) no reportable events (as defined in Item 16F(a)(1)(v) of Form 20-F).

About Yunji Inc.

Yunji Inc. is a leading social e-commerce platform in China that has pioneered a unique, membership-based model to leverage the power of social interactions. The Company’s e-commerce platform offers high-quality products at attractive prices across a wide variety of categories catering to the day-to-day needs of Chinese consumers. In addition, the Company uses advanced technologies including big data and artificial intelligence to optimize user experience and incentivize members to promote the platform as well as share products with their social contacts. Through deliberate product curation, centralized merchandise sourcing, and efficient supply chain management, Yunji has established itself as a trustworthy e-commerce platform with high-quality products and exclusive membership benefits, including discounted prices.

For more information, please visit https://investor.yunjiglobal.com/

Investor Relations Contact

Yunji Inc.
Investor Relations
Email: Yunji.IR@icrinc.com 
Phone: +1 (646) 224-6957

ICR, LLC
Robin Yang
Email: Yunji.IR@icrinc.com 
Phone: +1 (646) 224-6957

UNESCO honours Sharjah Ruler for Arabic historical dictionary

  • Issued by the Sharjah Government Media Bureau

PARIS, May 22, 2025 /PRNewswire/ — His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, a Supreme Council Member and the Ruler of Sharjah, was awarded a distinguished UNESCO honour upon the completion of the Historical Dictionary of the Arabic Language. At the official ceremony held at UNESCO’s headquarters in Paris, themed “Arabic Language: A Bridge Between Heritage and Knowledge”, Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, wife of His Highness the Ruler of Sharjah and chairperson of the Supreme Council for Family Affairs (SCFA), was present, along with Sheikha Bodour bint Sultan Al Qasimi, chairperson of the Sharjah Book Authority (SBA).

UNESCO honours Sharjah Ruler for Arabic historical dictionary
UNESCO honours Sharjah Ruler for Arabic historical dictionary

Upon his arrival at UNESCO headquarters, His Highness was received and warmly welcomed by Audrey Azoulay, Director-General of UNESCO; Fahd Saeed Al Raqbani, UAE Ambassador to France; Abdullah bin Mohammed Al Owais, Chairman of Sharjah’s Department of Culture; Jamal Al-Turaifi, President of Al Qasimia University; Ahmed bin Rakkad Al Ameri, CEO of the Sharjah Book Authority; Ali Al-Haj Al Ali, UAE Permanent Delegate to UNESCO; and Mohamed Hassan Khalaf, Director General of the Sharjah Broadcasting Authority.

His Highness the Ruler of Sharjah delivered a speech during the ceremony, stating, “It is my honour to stand among you today in this esteemed cultural forum at UNESCO, whose noble mission we revere and whose fruitful partnership we cherish. Together, we commemorate a groundbreaking scholarly and cultural milestone, the Historical Dictionary of the Arabic Language. This occasion is further enriched by its coincidence with the World Day for Cultural Diversity for Dialogue and Development, a day designated by UNESCO to promote mutual understanding and respect among cultures, reinforcing our collective humanity.

“Language, in all its forms, undeniably serves as the main repository of culture and the most authentic reflection of a community’s identity. In celebrating the Historical Dictionary of the Arabic Language today, we honour a vital aspect of our rich human diversity, represented by the Arabic language, which carries a deep civilisational heritage and has had a significant scientific and humanistic impact.”

His Highness subsequently emphasised the contributions of the partner institutions that played a role in the creation of the dictionary.

His Highness emphasised that all languages possess an equal right to exist and evolve, stating, “When we restore to Arabic its rightful history and highlight the aspects of its development, we simultaneously affirm to the world that every language is entitled to existence, progress and celebration, and that cultural justice demands that humanity not be reduced to a single tongue, nor the civilisations of peoples confined to one model. Just as biodiversity ensures the continuity of life, cultural and linguistic diversity secures the ongoing evolution and revitalisation of human creativity.”

He then conveyed his sincere appreciation to UNESCO for recognising the Historical Dictionary of the Arabic Language and for the collaborative cultural initiatives between Sharjah and the organisation:

He wrapped up with a call for unity: “Let us move forward together, dear friends, hand in hand, to enhance our cultural dialogue, to protect our common human heritage, and to guarantee that every culture’s voice is acknowledged, every language valued, and every people stay true to their genuine identity.”

At the ceremony, Audrey Azoulay, the Director-General of UNESCO, presented a speech to welcome His Highness the Ruler of Sharjah. She expressed her pleasure regarding the visit of the Sharjah delegation to Paris, acknowledging the emirate as a worldwide centre of knowledge and culture. Azoulay emphasised Sharjah’s significant investments in diverse areas that align with UNESCO’s mission, pointing out its achievement of multiple international cultural awards.

Azoulay praised the foresight of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, which has placed culture and knowledge at the heart of Sharjah’s policies. She recognised the emirate’s arrangements for various cultural events, festivals, and exhibitions that span multiple areas of culture, arts, and history.

She acknowledged Sharjah’s initiative in signing an agreement to digitise UNESCO’s archives, marking a significant step towards preserving the organisation’s vast collection of books and documents, some of which date back over 80 years. This initiative guarantees the protection of precious historical documents that detail various events, agreements, and initiatives.

Azoulay conveyed her appreciation for the successful completion of the Historical Dictionary of the Arabic Language, a significant accomplishment achieved under the guidance of His Highness the Ruler of Sharjah. Created by a multitude of researchers and editors from 20 linguistic institutions throughout the Arab world, this dictionary has earned recognition from the Guinness World Records as the largest historical dictionary.

At the conclusion of the ceremony, His Highness the Ruler of Sharjah graciously signed a copy of the Historical Dictionary of the Arabic Language and presented it as a gift to UNESCO.

UNESCO honours Sharjah Ruler for Arabic historical dictionary
UNESCO honours Sharjah Ruler for Arabic historical dictionary

 

UNESCO honours Sharjah Ruler for Arabic historical dictionary
UNESCO honours Sharjah Ruler for Arabic historical dictionary

 

 

 

Sigenergy Expands Manufacturing Network with One More Production Base

NANTONG, China, May 22, 2025 /PRNewswire/ — Sigenergy has officially broken ground on a smart manufacturing hub, marking a pivotal milestone in its global expansion strategy. As a key addition to the company’s production network, the facility will bolster manufacturing capabilities and enhance supply chain resilience across international markets.

Sigenergy Smart Manufacturing Hub Groundbreaking Ceremony
Sigenergy Smart Manufacturing Hub Groundbreaking Ceremony

As a cornerstone of Sigenergy’s long-term strategic roadmap, the manufacturing hub will focus on high-volume production of the company’s core products, including inverters, battery packs, and energy gateways. The project covers 115 acres, with a total built-up area of 115,000 square meters. Once operational, the facility is expected to add over 300,000 units to annual production capacity—significantly strengthening Sigenergy’s ability to meet growing global demand.

“The groundbreaking of our new manufacturing base marks a major milestone in Sigenergy’s strategic roadmap,” said Tony Xu, Founder and CEO of Sigenergy. “It demonstrates our commitment to advancing technology and scaling production to better serve customers worldwide and help shape a cleaner, smarter, and more efficient energy future.”

Sigenergy has quickly emerged as a global leader in the energy storage sector. In March 2025, the company ranked No. 1 in Australia’s battery market with a 17.4% share of blended capacity, according to SunWiz. It also secured the top global position in the stackable all-in-one Distributed Energy Storage System (DESS) category, holding a 24.3% market share, as reported by Frost & Sullivan.

The manufacturing hub is designed as a next-generation smart factory integrating production, R&D, logistics, and operations in line with global best practices. It features a fully digitalized, closed-loop system and full-lifecycle quality traceability to ensure transparency, efficiency, and control. Sustainability is embedded throughout, with eco-friendly construction, low-carbon operations, and environmentally conscious design, setting a benchmark for intelligent and green manufacturing.

 

Historic First: CUNY In USA Establishes ‘Achyuta Samanta India Initiative’ Research Institute

Dr Samanta also bestowed with the Presidential Medal by the Varsity in New York

BHUBANESHWAR, India, May 22, 2025 /PRNewswire/ — In a ground-breaking development that marks a proud moment for India, especially for Odisha, a premier research institute at the City University of New York (CUNY) has been named after renowned educationist and social reformer Dr. Achyuta Samanta (Founder of KIIT and KISS). The newly established ‘Achyuta Samanta India Initiative CUNY Crest Institute’ (ASIICCI) was inaugurated on Tuesday in the presence of distinguished academics and dignitaries from across the United States.

Dr. Achyuta Samanta Inaugurating the Research Institute Named in His Honour in the Presence of Senior City University of New York (CUNY) Officials.
Dr. Achyuta Samanta Inaugurating the Research Institute Named in His Honour in the Presence of Senior City University of New York (CUNY) Officials.

This historic move is the first time a research centre in the United States has been named after an Indian, making it a moment of immense pride not only for Dr. Samanta but also for the people of Odisha and the global KIIT and KISS community. The newly established institute will provide American students with opportunities to research on Odisha’s rich art and heritage. It will also focus on Dr. Samanta’s contribution to the socio-economic development of tribal communities and his achievements in the field of education.

Adding to this prestigious recognition, Dr. Samanta was conferred the highest honour of CUNY — the Presidential Medal — during the event. Reserved for individuals of exceptional global impact, the medal acknowledges Dr. Samanta’s transformative contributions to education, tribal upliftment, and humanitarian service. His grassroots work through KIIT and KISS has positively impacted over 80,000 tribal children, offering them quality education, dignity, and opportunity.

The idea for the research institute originated during the recent visit of Dr. Milton Santiago, President of Bronx Community College under CUNY, to KIIT and KISS in Bhubaneswar. Deeply inspired by Dr. Samanta’s journey and vision, Dr. Santiago proposed naming a research institute after him, a suggestion that received unanimous approval from the university board.

At the inauguration, Dr. Santiago remarked, “The Achyuta Samanta India Initiative will help American students from diverse backgrounds understand and engage with India’s tribal communities, cultural roots, and one of the world’s most impactful educational models.”

Dr. Samanta, who attended the event as the guest of honour, expressed profound gratitude and humility, stating that it is a moment of great pride and honour for him as an Odia and Indian to have a U.S. research institute named after him. He noted that it was not only a personal recognition but also a matter of pride for Odisha, KIIT, and KISS. He hoped that the institute would encourage greater research and understanding of Odisha’s art, literature, and culture, as well as his own work.

Founded 175 years ago, CUNY is a prestigious U.S. public university system encompassing 25 colleges and over 300,000 students from 122 countries. The establishment of ASIICCI under its umbrella demonstrates the global relevance of Dr. Samanta’s vision and Odisha’s intellectual heritage.

https://www.youtube.com/watch?v=qyXrdNyLR_g

 

 

EdgeCap-backed Comac Medical Group Expands with Acquisition of ILIFE Consulting, a French Early-phase Specialty CRO

Strategic acquisition marks significant step to establish pan-European footprint and deepens expertise in oncology and early-phase biotech clinical trials.

LONDON, May 22, 2025 /PRNewswire/ — Comac Medical Group (“Group”), based in the UK and backed by EdgeCap Partners, announced today the acquisition of ILIFE Consulting (“ILIFE”), a specialized Contract Research Organization (CRO) headquartered in Paris, France, renowned for its expertise in oncology, rare diseases, and complex biotech clinical trials.

The transaction represents a significant milestone for the Group on its journey to becoming the leading pan-European full-service CRO partner for small and medium-sized biopharma companies, and complements recent expansions into the United States, Germany, and the United Kingdom.

Founded in 2013 by Marina Iché, ILIFE has built a distinguished reputation for delivering high-value strategic consulting alongside clinical trial execution for biotech sponsors. ILIFE’s addition to the Group will leverage complementary expertise and reach, thus creating new opportunities for clients, who will benefit from a complete service offering, including enhanced capabilities in biostatistics, data management, pharmacovigilance, bioanalytical services, and Comac Medical’s state-of-the-art Early Phase Clinical Research Unit.

ILIFE’s founder and CEO, Marina Iché, will continue in her leadership role and become a significant shareholder in the Group to support strategic growth initiatives and to maintain continuity of ILIFE’s values and services that have driven its success positioning it as a trusted partner in the biotech ecosystem.

Marina Iché, Founder and CEO of ILIFE Consulting, stated:

“Partnering with EdgeCap and Comac Medical Group marks an exciting new chapter for ILIFE. We share a deep commitment to quality, innovation, client-centric and agile service delivery. We mobilize our resources and energy to ensure successful partnerships with our clients. We listen and capitalize on our expertise to identify and bring the best solutions to support our clients in achieving their goals productively and efficiently. Joining forces allows us to leverage additional resources, broaden our service portfolio, and better serve our clients across Europe and beyond. We rely on the competence and integrity of our team whose dedication and energy drive us to work swiftly towards obtaining actionable results. I remain fully committed to ensuring continuity in ILIFE’s services while pursuing our mission to bring meaningful innovation to patients.”

Chris Smyth, Incoming CEO of Comac Medical Group, said: 

“ILIFE Consulting’s expertise and established presence in the French biotech ecosystem significantly strengthen our capabilities as part of the Group. I look forward to working closely with Marina and the ILIFE team as we collaborate to create meaningful value for our stakeholders and deliver excellence across our expanded geographic and therapeutic landscape.”

Today’s announcement closely follows the Group’s recent leadership appointments and international expansion initiatives, including new executive appointments – Dr. Chris Smyth as incoming CEO (effective 1st September 2025), Christian Buhlmann as Chief Commercial Officer, and Peter Windisch as Chief Operations Officer – and Neil Ferguson as Chairman of the Board.  

About ILIFE Consulting

ILIFE Consulting is a Paris-based CRO specialized in early-phase oncology and biotech development. Since 2013, ILIFE has partnered with emerging biotech companies to deliver tailored strategic and operational support – from protocol design to full clinical trial execution, including first-in-human and multi-country studies. With deep expertise in oncology, rare diseases, novel therapeutic modalities, and complex regulatory environments, ILIFE accelerates timelines, optimizes data quality, and helps its clients make confident, value-driven decisions. Trusted by over 20 biotech sponsors across Europe, ILIFE’s senior team of scientific and clinical leaders is committed to delivering high-impact studies that bring innovation closer to patients.

www.Ilifeconsulting.com

About Comac Medical Group

Based in London, United Kingdom, Comac Medical Group is one of the leading pan-European, full-service CRO platforms striving to be the partner of choice for small and medium-sized biopharma clients globally. The Group is present in more than 30 countries across Western Europe and Central and Eastern Europe, providing a comprehensive range of early to late-phase drug development services across a variety of therapeutic areas including oncology, rare diseases, dermatology, gastroenterology, and respiratory diseases.

Comac Medical’s FDA and EMA-inspected Clinical Research Unit (CRU) for Phase I, bioavailability and bioequivalence studies has 20 years of experience in early-phase clinical research. Based in Sofia, the facility is the largest in the region and comprises 42 beds, an on-site pharmacy as well as a clinical and bioanalytical laboratory.

www.comac-medical.com 

About EdgeCap Partners

EdgeCap is a London- and Tallinn-based mid-market private equity and growth capital firm targeting investments into high-quality companies in Europe. We partner with ambitious founders and management teams to develop strong local businesses into pan-European and global champions. EdgeCap was founded in 2021 by Kristjan Piilmann and Chris Backes, who have 20+ years of combined private equity and investment banking experience at bulge bracket firms including PSG Equity LLP, Morgan Stanley, Citi and Goldman Sachs.

www.edgecap.eu

 

Gorilla Technology Shares Repurchase and Insider Ownership Updates; To Announce Q1 Earnings


London, United Kingdom – Newsfile Corp. – May 22, 2025 – Gorilla Technology Group Inc. (NASDAQ: GRRR) (“Gorilla” or the “Company”), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, today announced a series of significant developments underscoring its confidence in long-term value creation and sustained operational momentum.

Update on Share Repurchase Programme: Cumulative $5.4M

Gorilla successfully completed the repurchase of over $1.8 million worth of its own shares in April and May, capitalising on market dislocation and reinforcing its belief in the intrinsic value of the business. This strategic deployment of capital reflects the company’s confidence in its growth trajectory, operational execution and long-term fundamentals.

This brings the company’s cumulative share repurchases under the current buy-back programme to $5.4 million in the past twelve months, leaving $4.6 million remaining under the $10 million authorized by the Board. The company remains open to further opportunistic repurchases as cash buffers continue to strengthen.

Update on Insider Ownership: Approaches 20%

In a show of commitment and deep alignment with shareholder interests, the directors and officers of the company purchased additional shares in April and May during the permitted trading window. Collectively, Gorilla’s management and Board of Directors now control nearly 20% of the Company, reinforcing insider confidence and vested interest.

Upcoming Earnings Release

Gorilla Technology will release its financial results for the first quarter of 2025 in the first half of June, which will be followed by an investor call. The company is poised to report continued progress across key markets including Southeast Asia, USA, Latin America and the UK, driven by its AI-powered smart infrastructure solutions. Call information will be circulated shortly.

About Gorilla Technology Group Inc.

Headquartered in London U.K., Gorilla is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies.

Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.

For more information, please visit our website: Gorilla-Technology.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Gorilla’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, statements regarding our beliefs about future revenues, our ability to attract the attention of customers and investors alike, Gorilla’s ability to win additional projects and execute definitive contracts related thereto, along with those other risks described under the heading “Risk Factors” in the Form 20-F Gorilla will file with the Securities and Exchange Commission (the “SEC”) on April 30, 2025 and those that are included in any of Gorilla’s future filings with the SEC. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside of the control of Gorilla and are difficult to predict. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Gorilla undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

Investor Relations Contact:

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
GRRR@redchip.com

The issuer is solely responsible for the content of this announcement.

About Gorilla Technology Group Inc.

VinFuture 2025: 1,705 nominations worldwide – twelvefold increase in nominating partners over five seasons


HANOI, VIETNAM – Media OutReach Newswire – 22 May 2025 – The VinFuture Prize, a global science and technology award, has officially concluded the nomination period for its fifth season with a total of 1,705 nominations submitted from around the world. Notably, the number of official nominating partners has seen exceptional growth, reaching 14,772 – more than a twelvefold increase from the 1,200 recorded in the inaugural season – underscoring the Prize’s reputation as a global hub for scientific and intellectual excellence.

Inspired by the noble mission and unique values of the VinFuture Prize, the number of international scientists serving as official nominating partners has increased more than twelvefold compared to the 1,200 recorded in the inaugural season. Photo courtesy of VinFuture.
Inspired by the noble mission and unique values of the VinFuture Prize, the number of international scientists serving as official nominating partners has increased more than twelvefold compared to the 1,200 recorded in the inaugural season. Photo courtesy of VinFuture.

This season marks a significant leap in both the quantity and quality of nominations, as demonstrated by the wide engagement of the esteemed global scientific community. Among the nominating partners, the majority are from the Americas (31%), followed by Europe (28.6%), Asia (26.8%), Africa (7.1%), and Oceania (6.5%).

Among the 14,772 nominators, nearly half (7,240 experts) are affiliated with leading universities and research institutes worldwide. Institutions represented include Harvard University, the Massachusetts Institute of Technology, Stanford University (USA), the University of Cambridge, the University of Oxford (UK), the University of Melbourne (Australia), the University of Toronto (Canada), and the National University of Singapore (Singapore), among others. Notably, 1,395 nominators (9.4%) are scientists ranked among the top 2% most highly cited researchers globally, based on the prestigious list compiled by experts at Stanford University.

The nominations for the 2025 award season continue to span a comprehensive range of critical fields essential to human well-being and global sustainable development. These include medicine and healthcare (36.7%); energy, transportation, and construction (17.8%); environment and earth sciences (17.8%); and agriculture and food (11.3%). These core fields mirror global science and technology priorities, attracting considerable attention from the international community.

VinFuture’s nominating partners play a vital role in identifying and nominating groundbreaking scientific innovations for well-deserved recognition. These innovations demonstrably benefit humanity on a global scale while also amplifying the VinFuture Prize’s stature within the international scientific community.

Driven by the Prize’s profound mission and global vision, all nominators participate on a voluntary basis. In 2024, following a nomination by Professor Monica Lam, a leading computer scientist at Stanford University (USA), Mr. Jensen Huang, CEO and co-founder of NVIDIA, was honored as one of the 2024 VinFuture Grand Prize Laureates for his industry-driven contributions to the advancement of deep learning.

Dr. Thai-Ha Le, Managing Director of the VinFuture Foundation, remarked: “Our five-year commitment to the mission of ‘Science for Humanity’ has establisheds VinFuture as an international beacon of scientific excellence and hope. The exponential growth in nominating partners and the exceptional quality of this year’s nominations not only underscore the growing trust of the international scientific community in the Prize, but also highlight the urgent need for science and technology solutions to build a world where humanity thrives in harmony with a sustainable environment.

The 2025 VinFuture pre-screening round will take place from May 26 to August 31. Its goal is to enable the 10-member Pre-Screening Committee to meticulously evaluate the most impactful and award-worthy nominations for advancement to the final round. In pursuit of scientific integrity, objectivity, and transparency, the Committee will assess the nominations through a rigorous evaluation process based on the highest international standards and core criteria. These criteria include the degree of scientific or technological advancement, the impact on people’s lives, and the project’s scale and sustainability.

Within just five years, the VinFuture Prize has rapidly established its international stature and prestige, as evidenced by the growing list of laureates honored with prestigious global accolades. Notable examples include Dr. Katalin Karikó and Prof. Drew Weissman (laureates of the 2021 VinFuture Grand Prize and 2023 Nobel Prize in Physiology or Medicine); Dr. Demis Hassabis and Dr. John Jumper (laureates of the 2022 VinFuture Special Prize and 2024 Nobel Prize in Chemistry); Prof. Geoffrey Hinton (laureate of the 2024 VinFuture Grand Prize and 2024 Nobel Prize in Physics); Prof. Yoshua Bengio, Prof. Geoffrey Hinton, Mr. Jensen Huang, Prof. Yann LeCun, and Prof. Fei-Fei Li (laureates of the 2024 VinFuture Grand Prize and 2025 Queen Elizabeth Prize for Engineering); and Prof. Daniel Joshua Drucker, Prof. Joel Francis Habener, Prof. Jens Juul Holst, and Assoc. Prof. Svetlana Mojsov (laureates of the 2023 VinFuture Special Prize and 2025 Breakthrough Prize).

Hashtag: #VinFuture

The issuer is solely responsible for the content of this announcement.

VinFuture

The VinFuture Foundation, established on International Human Solidarity Day on December 20th, 2020, is a non-profit organization co-founded by billionaire Mr. Pham Nhat Vuong and his wife, Mrs. Pham Thu Huong. The Foundation’s core activity is awarding the annual VinFuture Prize, which recognizes transformative scientific and technological innovations capable of making significant positive changes in the lives of millions of people worldwide.

The VinFuture Prize consists of four prestigious awards presented each year. The most esteemed prize is the VinFuture Grand Prize, valued at US$3 million, making it one of the largest annual prizes globally. Additionally, there are three Special Prizes, each valued at US$500,000, specifically dedicated to honoring Women Innovators, Innovators from Developing Countries, and Innovators with Outstanding Achievements in Emerging Fields.

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates Department of Health to Commence Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin

The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE

Philadelphia, Pennsylvania – Newsfile Corp. – May 22, 2025 – Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”) is pleased to announce that it has received study may proceed approval from the UAE DOH to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC of the skin.

The study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD).

Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

Clinical Trial Design (SKNJCT-004)

The clinical study, SKNJCT-004, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 36 subjects presenting with BCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA.

The high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company’s Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021.

SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of BCC.

The Company also has SKNJCT-003 Phase 2 clinical study currently underway in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The company also announced expanding clinical trial sites in Europe.

In April 2025, the company also announced entering into a binding letter of intent to acquire Antev Ltd. (“Antev“), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate.

For further information contact:

Carolyn Bonner, President
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd:

Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in UAE.

In April 2025, the company also announced entering into a binding letter of intent to acquire Antev Ltd. (“Antev“), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the potential Antev transaction, including the entry into a definitive agreement in respect of the Antev transaction, the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company’s plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study, the Company’s intention to complete and submit an interim data analysis to the FDA and to request a Type C meeting and the timing thereof, the Company’s aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s public filings on SEDAR+ and on EDGAR, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Company’s long form prospectus accessible on the Company’s profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The issuer is solely responsible for the content of this announcement.